The scientific community is carefully watching this groundbreaking treatment, a innovative agonist targeting both glucagon-like peptide-1 and GIP. Initial trials suggest it is likely to offer impressive improvements in obesity management compared to current medications, perhaps representing a major step forward in the management of excess weight… Read More